• search
For Quick Alerts
For Daily Alerts

Avesthagen announces launch of Teestar

By Staff

Bangalore, Apr 23 (UNI) Avesthagen Ltd, a leading knowledge based life sciences company, today announced the launch of clinically validated bioactive Teestar, aimed at promoting wellness through better blood sugar management.

The product, which comes in both capsule and cracker formations, was made from natural ingredients and would be available from May 15 throughout the country, company Founder-Chairman and Managing Director Viloo Morawala Patell said.

Speaking to newspersons here, she said Avesthagen had used two of its patented technologies to develop Teestar -- Adept, a comprehensive database that brought together traditional medicine with modern systems biology, created under world bank's funding SPREAD project, and MetaGrid, a unique algorithm that enabled comprehensive constituent profiling of the plant extracts.

Dr Patell said at present India had 35 million Diabetics and was poised to become the world's Diabetes capital by the year 2025.

Teestar, more a food supplement than a Diabetes drug, would help keep down the blood sugar levels by more than 20 per cent.

The clinical trials were carried out by independent clinical research organisations INTOX of Pune and Manipal AcuNova Ltd in the city. Teestar had proven to be safe in both studies and no adverse reactions were noticed during the studies, she said.

''In the field of functional foods, we have made next level achievement by introducing Teestar. The product has been evolved after understanding the science behind the activity and designing the clinical studies to prove the concept, keeping all parental variables in check using Avesthagen technology,'' Dr Patell said.

The product was first of the seven bioactives and this would be followed by many more in the pipeline, she added.


For Daily Alerts
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more